PAI
JUNO

Pittenger & Anderson Inc’s Juno Therapeutics, Inc. JUNO Stock Holding History

Pittenger & Anderson Inc’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-45
Closed -$1K – 392
2016
Q3 		$1K Hold
45
– – ﹤0.01% 361
2016
Q2 		$2K Hold
45
– – ﹤0.01% 368
2016
Q1 		$2K Sell
45
-30
-40% -$1.04K ﹤0.01% 374
2015
Q4 		$3K Hold
75
– – ﹤0.01% 391
2015
Q3 		$3K Buy
+75
New +$3.29K ﹤0.01% 423

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pittenger & Anderson Inc's JUNO Position: Q4 2016 in Review

Pittenger & Anderson Inc sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 45 shares — an estimated $1K sold.

Pittenger & Anderson Inc first reported a position in JUNO in Q3 2015 and held it in 5 quarters. The position peaked at $3K in Q4 2015. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Pittenger & Anderson Inc reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 45 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $1K.
  • Pittenger & Anderson Inc first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 5 quarters.
  • Pittenger & Anderson Inc's Juno Therapeutics, Inc. position peaked at $3K in Q4 2015.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Pittenger & Anderson Inc's 13F filing for Q4 2016, filed 16 Feb 2017.